- Home
- MYGN vs DSU Comparison
MYGN vs DSU Comparison
Compare MYGN & DSU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- DSU
- Stock Information
- Founded
- MYGN 1991
- DSU 1998
- Country
- MYGN United States
- DSU United States
- Employees
- MYGN N/A
- DSU N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DSU Finance Companies
- Sector
- MYGN Health Care
- DSU Finance
- Exchange
- MYGN Nasdaq
- DSU Nasdaq
- Market Cap
- MYGN 642.0M
- DSU 548.1M
- IPO Year
- MYGN 1995
- DSU N/A
- Fundamental
- Price
- MYGN $8.33
- DSU $10.33
- Analyst Decision
- MYGN Hold
- DSU
- Analyst Count
- MYGN 13
- DSU 0
- Target Price
- MYGN $13.50
- DSU N/A
- AVG Volume (30 Days)
- MYGN 959.5K
- DSU 148.2K
- Earning Date
- MYGN 11-04-2025
- DSU 01-01-0001
- Dividend Yield
- MYGN N/A
- DSU 10.06%
- EPS Growth
- MYGN N/A
- DSU N/A
- EPS
- MYGN N/A
- DSU N/A
- Revenue
- MYGN $832,900,000.00
- DSU N/A
- Revenue This Year
- MYGN $0.06
- DSU N/A
- Revenue Next Year
- MYGN $5.68
- DSU N/A
- P/E Ratio
- MYGN N/A
- DSU N/A
- Revenue Growth
- MYGN 3.83
- DSU N/A
- 52 Week Low
- MYGN $3.76
- DSU $9.22
- 52 Week High
- MYGN $22.92
- DSU $11.40
- Technical
- Relative Strength Index (RSI)
- MYGN 64.16
- DSU 46.58
- Support Level
- MYGN $7.68
- DSU $10.08
- Resistance Level
- MYGN $8.25
- DSU $10.54
- Average True Range (ATR)
- MYGN 0.38
- DSU 0.08
- MACD
- MYGN -0.01
- DSU 0.00
- Stochastic Oscillator
- MYGN 78.80
- DSU 58.62
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About DSU Blackrock Debt Strategies Fund Inc.
Blackrock Debt Strategies Fund Inc is a diversified, closed-end management investment company. Its investment objective is to provide current income by investing in a diversified portfolio of U.S. companies' debt instruments including corporate loans. The fund's secondary investment objective is to provide capital appreciation.